- Home
- PLRX
as 04-18-2025 1:41pm EST
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 87.0M | IPO Year: | 2020 |
| Target Price: | $9.79 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Hold | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.10 - $16.52 | Next Earning Date: | 05-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -42.86% |
Latest Pliant Therapeutics Inc. News
PLRX Breaking Stock News: Dive into PLRX Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know
GlobeNewswire
12 days ago
Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
Zacks
23 days ago
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know
MT Newswires
a month ago
Pliant Therapeutics Says Experimental Cancer Drug Shows Antitumor Activity in Phase 1 Trial
GlobeNewswire
a month ago
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
BioPharma Dive
a month ago
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’
MT Newswires
a month ago
Pliant Therapeutics Signs Shareholder Rights Agreement
GlobeNewswire
a month ago
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
Compare PLRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PLRX Pliant Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.